MedTrace Logo

A Study of IMR-687 in Subjects With Sickle Cell Disease

NCT04474314 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2025-05-15

Study results available
· View outcomes & findings →

Summary

A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease

Conditions

Interventions

DRUG

IMR-687

Oral administration of once daily IMR-687

DRUG

Placebo

Oral administration of once daily Placebo

Sponsors & Collaborators

  • Imara, Inc.

    collaborator INDUSTRY

  • Cardurion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Kenneth Attie, MD · Imara, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-13
Primary Completion
2022-03-02
Completion
2022-05-04
FDA Drug
Yes

Countries

  • United States
  • Ghana
  • Greece
  • Italy
  • Kenya
  • Lebanon
  • Morocco
  • Netherlands
  • Oman
  • Senegal
  • Tunisia
  • Uganda
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04474314 on ClinicalTrials.gov